Boulogne-sur-Mer Hospital Introduces Nuclear Therapy for Metastatic Prostate Cancer
The Boulogne-sur-Mer hospital center in Pas-de-Calais has introduced a targeted nuclear medicine therapy for patients suffering from advanced metastatic prostate cancer, marking a new phase in regional oncological care as of November 20, 2026, according to Actu.
Key Clinical Takeaways:
- The therapy uses a radioactive lutetium-177 isotope coupled with a PSMA-targeting molecule to destroy cancer cells from within while sparing healthy tissue.
- Clinical data indicates the treatment can increase survival duration by 35% and significantly delay the decline of quality of life for patients with advanced disease.
- The treatment is currently administered in an outpatient setting, following certification from the Haute Autorité de Santé (HAS).
Targeted Radioligand Therapy Mechanism
The treatment functions as a form of “targeted radioactive chemotherapy,” according to the hospital center. It utilizes the Prostate Specific Membrane Antigen (PSMA), a protein that is overexpressed on the surface of prostate cancer cells in 75% to 95% of patients, as reported by Sciences et Avenir.
By coupling the lutetium-177 isotope to a molecule designed to bind specifically to this protein, clinicians ensure the radiation is delivered directly to both the primary tumor and metastatic sites throughout the body.
This approach, known as vectorized internal radiotherapy, minimizes systemic exposure compared to conventional chemotherapy. When the medication is injected, it circulates through the organism, fixes itself to cancerous cells wherever they are located, and irradiates them while preserving surrounding healthy tissues, Sciences et Avenir noted.
Therapy Shows 35% Survival Increase for Advanced Patients
The implementation of this therapy follows years of clinical development. More recent data, including findings published this summer in The Lancet, have continued to refine the understanding of these radioligands.
For patients with advanced metastatic forms, the treatment has demonstrated significant clinical benefits. “It has allowed for a 35% increase in their survival duration and delayed the degradation of their quality of life,” Sciences et Avenir reported. This therapy is currently authorized in France specifically for this patient population, though researchers are investigating its use in earlier stages of the disease.
Active Surveillance Recommended for Non-Significant Tumors
The rise of these targeted therapies coincides with evolving standards in prostate cancer detection. While early diagnosis remains a priority, clinical focus has shifted toward balancing detection with the avoidance of overdiagnosis and overtreatment. Since 2017, official recommendations have favored active surveillance for tumors deemed clinically “non-significant,” according to Yann Neuzillet, a urologist at the Foch Hospital in Hauts-de-Seine, as cited by Sciences et Avenir.
Screening efficacy is supported by long-term data. A Swedish study published in European Urology in 2019 demonstrated that organized screening for men aged 50 to 69, involving blood-based PSA testing and biopsy, reduced mortality by 21% over a 16-year follow-up period, according to Sciences et Avenir. Furthermore, a review from the Cochrane Library concluded that such programs reduce prostate cancer-related deaths by approximately 2 per 1,000 men screened.
Future Trajectory of Radioligand Development
The medical community is currently exploring the next generation of radioligands, including those coupled with actinium-225 or terbium-161, which are undergoing preliminary trials. The expansion of these treatments to broader patient groups, particularly those at earlier stages of metastatic disease, depends on proving that they can reliably extend survival in those populations.
Patients seeking specialized care or information regarding advanced prostate cancer treatments should consult with board-certified urologists or oncologists familiar with nuclear medicine protocols. These specialists can evaluate whether a patient meets the specific clinical criteria for PSMA-targeted therapies or other modern oncological interventions. Establishing a clear care pathway with a multidisciplinary oncology team remains the standard for managing metastatic disease.
Whether regulatory authorities will extend reimbursement for these therapies to earlier clinical stages remains the primary question, as evidence must confirm that the survival benefits observed in advanced cases hold true for patients earlier in their disease progression. The hospital in Boulogne-sur-Mer continues to offer this care in an outpatient setting, having recently received a “Confirmed Quality of Care” certification from the Haute Autorité de Santé.
Located on the Côte d’Opale along the English Channel, Boulogne-sur-Mer serves as a major port city in Northern France and currently stands as the country’s largest fishing port.
Its history as a strategic maritime hub dates back to the Roman Empire, when the settlement—then known as Gesoriacum—served as the primary port for trade and communication with Britain. By the 12th century, the city had established itself as a significant center for the herring trade, an industry that remains central to its identity today.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading
- Vegan News Publishes Chinese Tofu Skin Roll Recipe with Shiitake and Bamboo Shoots
- Murmu Inaugurates ICMR-NIMR Jubilee, Says Malaria Fell 80%
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)
- Study Finds Nano Nitazoxanide Kills Oral Cancer Cells Better (time.news)